Bibliography
- Mancini JA, Abramovitz M, Cox ME, et al. 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett 1993;318:277-81
- Evans JF, Ferguson AD, Mosley RT, et al. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29:72-8
- Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990;343:278-81
- Evans JF, Leville C, Mancini JA, et al. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol 1991;40:22-7
- Gillard J, Ford-Hutchinson AW, Chan C, et al. L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 – dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1989;67:456-64
- Brideau C, Chan C, Charleson S, et al. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can J Physiol Pharmacol 1992;70:799-807
- Kolasa T, Gunn DE, Bhatia P, et al. Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesis. J Med Chem 2000;43:3322-34
- Muller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, et al. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Ther 1993;267:51-7
- Vickers PJ, Adam M, Charleson S, et al. Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors. Mol Pharmacol 1992;42:94-102
- Ferguson AD, McKeever BM, Xu S, et al. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007;317:510-2
- Abramovitz M, Wong E, Cox ME, et al. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 1993;215:105-11
- Fruchtmann R, Mohrs KH, Hatzelmann A, et al. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions 1993;38:188-95
- Dahlen B, Kumlin M, Ihre E, et al. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax 1997;52:342-7
- Diamant Z, Timmers MC, van der Veen H, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95:42-51
- Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993;147:839-44
- Hamilton AL, Watson RM, Wyile G, et al. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997;52:348-54
- Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36:233-9
- Kaushal R, Pal P, Alwell K, et al. Association of ALOX5AP with ischemic stroke: a population-based case-control study. Hum Genet 2007;121:601-7
- Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 2006;112:701-18
- Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007;61:663-76
- Available from: http://www.drugs.com/news/merck-outlines-long-term-prospects-progress-strategic-plan-2008-annual-business-briefing-15112.html
- Merck&Co., Inc. WO2005009951; 2005
- Merck&Co., Inc. WO2006098912; 2006
- Merck&Co., Inc. WO2006044602; 2006
- Merck&Co., Inc. WO2007056210; 2007
- Merck&Co., Inc. WO2007120574; 2007
- Available from: http://www.amirapharm.com/articles/Nov01-AM103PhaseIResults.html
- Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA 2005;293:2245-56
- Available from: http://www.pipelinereview.com/content/view/7108/111/
- Available from: http://msnmoney.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHTML1?ID=5806181& SessionID=6yCxW8rKa94lGg9